11月17日 - ** 通用电气医疗集团GEHC.O称，美国最大的私营心脏病学团体网络Cardiovascular Associates of America(CVAUSA) 计划扩大采用该公司的Flyrcado注射液。
** Flyrcado 是一种医用染料，用于心脏扫描，以检查血液流动情况。
** 与 CVAUSA 的交易可带来价值超过 3 亿美元的年化收入机会--Evercore ISI
** CVAUSA表示计划在约25个医疗点使用Flyrcado
** 虽然在 25 个站点的采用速度将决定 GEHC 达到 3 亿美元以上年收入峰值的时间，但我们认为经济激励措施和形象质量为更快的采用周期提供了强有力的理由"- Evercore
** 截至收盘，股价累计下跌 6.4
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.